Iovance Biotherapeutics Inc (NAS:IOVA)
$ 8.88 -0.115 (-1.28%) Market Cap: 2.48 Bil Enterprise Value: 2.21 Bil PE Ratio: 0 PB Ratio: 3.65 GF Score: 39/100

Iovance Biotherapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 14, 2023 / 06:00PM GMT
Release Date Price: $6.65 (+2.31%)
Mark Breidenbach
Oppenheimer & Co. Inc. - Analyst

Okay. Hello, everyone. Thanks again for joining us on day two of Oppenheimer's 33rd Annual Healthcare Conference. My name is Mark Breidenbach, I'm one of the biotech analysts here at Oppenheimer.

This afternoon, I'm pleased to be hosting a fireside chat with Iovance, which is developing a pipeline of tumor infiltrating lymphocyte, or TIL, cellular therapies for cancer. We believe Iovance's a lead product candidate lifileucel could receive accelerated approval later this year.

And joining us for today's discussion is the company's CFO, Jean-Marc Bellemin. We'll be sure to leave -- try to leave a few minutes at the end for Q&A. So feel free to make use of the question -- ask-a-question button on your browser if you want to submit anything to me to relay to Jean-Marc. But with that said, let's go ahead and dive right into the discussion.

So Jean-Marc, first of all, thanks for joining us today. And I hope you don't mind if I ask you some questions that are a little more focused on regulatory issues than on financial issues

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot